Cure My Disease

Don't miss your cure!

 Log in / Sign up

Drug tested in kids with MS after other treatments fail

NCT ID NCT03368664

Terminated Disease control Sponsor: Genzyme, a Sanofi Company Source: ClinicalTrials.gov ↗

Summary

This study tested a drug called alemtuzumab in children and teenagers (ages 10-17) with relapsing multiple sclerosis (MS) whose disease was still active despite being on other standard MS medications. The goal was to see if switching to alemtuzumab could better control their MS by reducing new brain lesions and relapses. The study was terminated early and enrolled only 16 participants over a planned 5-year period.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Investigational Site Number : 0400001

    Vienna, 1090, Austria

  • Investigational Site Number : 2500001

    Le Kremlin-Bicêtre, 94270, France

  • Investigational Site Number : 2500002

    Strasbourg, 67091, France

  • Investigational Site Number : 3800001

    Milan, 20132, Italy

  • Investigational Site Number : 3800004

    Naples, Napoli, 80131, Italy

  • Investigational Site Number : 3800005

    Cagliari, 09126, Italy

  • Investigational Site Number : 6160001

    Warsaw, 04-730, Poland

  • Investigational Site Number : 6160002

    Poznan, Greater Poland Voivodeship, 60-355, Poland

  • Investigational Site Number : 6160003

    Lodz, Lódzkie, 93-338, Poland

  • Investigational Site Number : 6430001

    Moscow, 119602, Russia

  • Investigational Site Number : 6430002

    Saint Petersburg, 197110, Russia

  • Investigational Site Number : 6430004

    Moscow, 129110, Russia

  • Investigational Site Number : 6430005

    Saint Petersburg, 197022, Russia

  • Investigational Site Number : 7920001

    Ankara, 06500, Turkey (Türkiye)

  • Investigational Site Number : 7920003

    Istanbul, 34390, Turkey (Türkiye)

  • Investigational Site Number : 8260002

    London, London, City of, WC1N 3JH, United Kingdom

Conditions

Explore the condition pages connected to this study.

MULTIPLE SCLEROSIS